Atea Pharma rises as combo drug meets main goal in mid-stage study

Atea Pharmaceuticals

04/12/2024 13:03

** Shares of drug developer Atea Pharmaceuticals  AVIR.O 
rise 6.9% to $3.72 premarket 
    ** Co says its drug combination met the main goal for
treating Hepatitis C Virus (HCV) in a mid-stage study
    ** The combination of bemnifosbuvir and ruzasvir showed 98%
success rate in eliminating HCV, co says
    ** Bemnifosbuvir and ruzasvir are both oral antiviral
medications to treat HCV 
    ** HCV is a leading cause of chronic liver diseases and
liver transplants, affecting around 50 mln people worldwide
    ** As of last close, stock had risen 14.1% YTD

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))